A big step forward for ASX company research

Stuart Roberts

Pitt Street Research’s bread and butter is issuer-sponsored research of companies that are publicly traded on the ASX. We are big believers in the power of issuer sponsorship to enlarge the pool of quality, widely accessible research on ASX-listed companies, and thereby contribute to the overall efficiency of the Australian... Show More

Invitrocue - this Singapore company can predict cancer treatment outcomes

Stuart Roberts

Last week I published a report on a great Life Sciences company out of Singapore called Invitrocue. Singapore is one of the finest places a global traveler could find to do Life Sciences, ranking probably the seventh most-productive Life Sciences jurisdiction on the planet in terms of the amount of... Show More

Is this the start of the Australian Life Science Boom? The Viralytics/Merck deal is telling you something...

Stuart Roberts

Just over eighteen months ago, in July 2016, I published an article headlined 'The Coming Boom in Life Sciences, Down Under' in which I suggested that Australia was on the way to a boom for its biotech and medical device sector. I argued that all the elements of that coming... Show More

Dimerix - the little Aussie company that is now a big player in Diabetic Nephropathy

Stuart Roberts

I love it when ASX-listed Life Science companies generate pleasant surprises. For the last year or so we at NDF Research have been following Dimerix, a drug developer whose lead candidate, DMX-200, is showing promise in the treatment of kidney disease. DMX-200 is a combination of two existing drugs, irbesartan... Show More

Dimerix's Phase 2 success for DMX-200 - an important potential new treatment option for kidney disease

Stuart Roberts

In August of last year NDF Research initiated on Dimerix (ASX: DXB), a Melbourne and Perth-based drug discovery company being built around new ways to identify drugs acting on G Protein-Coupled Receptors. Dimerix's platform is important because GPCRs are the target of a significant number of the world’s best-selling drugs.... Show More

ResApp Health - First major clinical study of ResAppDx reports important data

Stuart Roberts

In July 2016 NDF research initiated coverage on ResApp Health, a company developing a smartphone-based diagnostic for respiratory disease. ResApp has just reported important data from the first major clinical study of the ResAppDx, a smartphone-based diagnostic for respiratory disease which we have previously called the ResApp System. This Australian... Show More

No comments.